Recursion Pharmaceuticals, Inc.(RXRX),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community - To The Moon

At the request of the exchanges, the U.S./Hong Kong stock quotes are displayed on a 15-minute delay, download the APP to view the real-time quotes for free.

Close

RXRX Recursion Pharmaceuticals, Inc.

Trading 08-24 10:28:27 EDT

3.24

-0.26

-7.35%

High3.44	Low3.22	Vol6.22M
Open3.41	D1 Closing3.50	Amplitude6.43%
Mkt Cap1.73B	Tradable Cap1.69B	Total Shares535.00M
T/O20.42M	T/O Rate1.19%	Tradable Shares522.33M
P/B--	ROE--	EPS0.00
52wk High--	52wk Low--	P/E--
Dividend--	Div.Yield--	ROA--

Loading ...

{"stockData":{"symbol":"RXRX","market":"US","secType":"STK","nameCN":"Recursion Pharmaceuticals, Inc.","latestPrice":3.2426,"timestamp":1787581706573,"preClose":3.5,"halted":0,"volume":6218260,"delay":0,"changeRate":-0.07354285714285716,"floatShares":522325546,"shares":534999999,"eps":-1.021913,"marketStatus":"Trading","change":-0.2574,"latestTime":"08-24 10:28:27 EDT","open":3.41,"high":3.44,"low":3.215,"amount":20421177.488812,"amplitude":0.064286,"askPrice":3.25,"askSize":5068,"bidPrice":3.24,"bidSize":3916,"shortable":3,"etf":0,"ttmEps":-1.021913,"tradingStatus":2,"nextMarketStatus":{"tag":"Post-Mkt","tradingStatus":3,"beginTime":1787601600000},"marketStatusCode":2,"adr":0,"listingDate":1618545600000,"exchange":"NASDAQ","adjPreClose":3.5,"preHourTrading":{"tag":"盘前","latestPrice":3.41,"preClose":3.5,"latestTime":"09:29 EDT","volume":161909,"amount":562742.9988114,"timestamp":1787578199915,"change":-0.09,"changeRate":-0.025714,"amplitude":0.054286},"postHourTrading":{"tag":"盘后","latestPrice":3.5,"preClose":3.5,"latestTime":"19:59 EDT","volume":174125,"amount":609351.8967,"timestamp":1787356788574,"change":0,"changeRate":0,"amplitude":0.014286},"volumeRatio":2.020997,"impliedVol":0.8228,"impliedVolPercentile":0.3426},"requestUrl":"/m/hq/s/RXRX","defaultTab":"news","newsList":[{"id":"1184081263","title":"Nvidia Faces Major Test This Week as AI Market's Bellwether","url":"https://stock-news.laohu8.com/highlight/detail?id=1184081263","media":"Bellwether Stocks Movement","labels":[],"top":1,"itemType":null,"share":"https://ttm.financial/m/news/1184081263?lang=en_us&edition=fundamental","pubTime":"2026-08-24 08:51","pubTimestamp":1787532702,"startTime":"0","endTime":"0","summary":"","market":"us","thumbnail":"https://static.tigerbbs.com/55424f784af2130e0629c0c4a06352c9","type":0,"news_type":0,"thumbnails":["https://static.tigerbbs.com/55424f784af2130e0629c0c4a06352c9"],"rights":null,"property":[],"language":"en","translate_title":"","themeId":"ba838cf5900a47de94e1e2f5f87b6072","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":true,"source_rank":0,"column":"","sentiment":"0","news_top_title":"Nvidia Faces Major Test This Week as AI Market's Bellwether","news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["NBIS","ARMG","TM","ARMW","SOUX","NBIL","APLX","ARMU","MIC","NBIG","NNOX","SOUN","NBIC","NEBX","ARMA","ARM","NVDA","RXRX","MUZ","AUR","MUYY","INVZ","MUG","NBIZ","SERV","MULL","APLD","ARBE","MU","CRNC","MUU","APLZ","MUD"],"isVideo":true,"video":{"duration":204,"video_url":"https://news-video-sg.skytigris.cn/videos/remotion/592/render_592_1787532364600.mp4","video_thumbnail":"https://news-video-sg.skytigris.cn/videos/covers/592.webp","audio_url":"https://news-video-sg.skytigris.cn/videos/remotion/592/tts/voiceover_ff80b9e7919d10e9.mp3","isAI":true},"gpt_icon":0},{"id":"1181557292","title":"Nvidia Q2 FY27 Earnings: Gross Margin, Q3 Guidance in Focus","url":"https://stock-news.laohu8.com/highlight/detail?id=1181557292","media":"Bellwether Stocks Movement","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1181557292?lang=en_us&edition=fundamental","pubTime":"2026-08-21 09:10","pubTimestamp":1787274627,"startTime":"0","endTime":"0","summary":"","market":"sg","thumbnail":"https://static.tigerbbs.com/16c0a892a1297fbe5aa585282447dcb8","type":0,"news_type":0,"thumbnails":["https://static.tigerbbs.com/16c0a892a1297fbe5aa585282447dcb8"],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":true,"source_rank":0,"column":"","sentiment":"0","news_top_title":"Nvidia Q2 FY27 Earnings: Gross Margin, Q3 Guidance in Focus","news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["ARMW","APLD","SOUN","MU","NBIL","ARM","NNOX","ARBE","MUG","NEBX","NVD","MIC","MUU","MUYY","MUZ","BK4609","NVDL","ARMU","SOUX","MUD","NVDS","NBIZ","NVDA","07388","CRNC","09788","SNVDA2609","07788","APLX","ARMG","TM","APLZ","MULL","NBIS","RXRX","INVZ","SERV","AUR","09388"],"isVideo":true,"video":{"duration":136,"video_url":"https://news-video-sg.skytigris.cn/videos/remotion/557/render_557_1787274323198.mp4","video_thumbnail":"https://news-video-sg.skytigris.cn/videos/covers/557.webp","audio_url":"https://news-video-sg.skytigris.cn/videos/remotion/557/tts/voiceover_cd0e5b9e8f315bbc.mp3","isAI":true},"gpt_icon":0},{"id":"2660435025","title":"Contineum, Disc Medicine, Recursion Advance Pipelines Ahead of Catalysts, Morgan Stanley Says","url":"https://stock-news.laohu8.com/highlight/detail?id=2660435025","media":"MT Newswires Live","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2660435025?lang=en_us&edition=fundamental","pubTime":"2026-08-17 23:01","pubTimestamp":1786978897,"startTime":"0","endTime":"0","summary":"Contineum Therapeutics , Disc Medicine , and Recursion Pharmaceuticals  are making meaningful pipeline progress, with key clinical and regulatory catalysts ahead in 2026, Morgan Stanley said in a note Monday.Contineum had a solid Q2, with the company advancing PIPE-791 toward a potentially large idiopathic pulmonary fibrosis opportunity, backed by strong trial progress, better tolerability, additional chronic-pain potential, and enough cash to fund operations through mid-2029, the investment firm said.Morgan Stanley said Disc Medicine is seeing \"very strong\" demand for bitopertin, with its expanded access program launched ahead of a phase 3 trial readout expected in Q4. Management says demand is currently limited by operational bandwidth, not patient interest, according to the note.Recursion Pharmaceuticals is showing growing validation of its artificial intelligence drug-discovery platform, the firm said. The company cut its 2026 cash spending forecast to about $375 million from rough","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["CTNM","BK4611","IRON","LU0053671581.USD","BK4548","BK4139","RXRX","BK4007","BK4609","BK4539"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2660489363","title":"Morgan Stanley Adjusts PT on Recursion Pharmaceuticals to $5.30 From $5.50, Keeps Equalweight Rating","url":"https://stock-news.laohu8.com/highlight/detail?id=2660489363","media":"MT Newswires Live","labels":["express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2660489363?lang=en_us&edition=fundamental","pubTime":"2026-08-17 17:54","pubTimestamp":1786960445,"startTime":"0","endTime":"0","summary":"Recursion Pharmaceuticals (RXRX) has an average rating of overweight and mean price target of $7.22, according to analysts polled by FactSet.(MT Newswires covers equity, commodity and economic researc","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate","earning"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"express","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["RXRX","BK4611","BK4539","BK4139","BK4548","BK4609"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2657665036","title":"Recursion Director Blake Borgeson Disposes of 30,000 Shares for $97,500","url":"https://stock-news.laohu8.com/highlight/detail?id=2657665036","media":"Reuters","labels":["shareholding","insiderTrades"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2657665036?lang=en_us&edition=fundamental","pubTime":"2026-08-07 05:24","pubTimestamp":1786051497,"startTime":"0","endTime":"0","summary":"Recursion director Blake Borgeson disposes of 30,000 shares for $97,500Recursion Pharmaceuticals director Blake Borgeson sold 30,000 Class A common shares on Aug. 4 at $3.25.Direct holdings fell to 6,","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260806:nNDL9pSDDB:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":"Recursion Director Blake Borgeson Disposes of 30,000 Shares for $97,500","news_tag":"shareholding,insiderTrades","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4539","RXRX","BK4548","BK4139","BK4611","BK4609"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2657656215","title":"Primer: Recursion Pharmaceuticals  (RXRX US) - Aug 2026","url":"https://stock-news.laohu8.com/highlight/detail?id=2657656215","media":"Smartkarma","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2657656215?lang=en_us&edition=fundamental","pubTime":"2026-08-06 16:29","pubTimestamp":1786004987,"startTime":"0","endTime":"0","summary":"utm_source=tiger_community","market":"other","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.smartkarma.com/home/private-investor-solutions/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["RXRX","BK4611","BK4548","BK4539","BK4609","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2657522957","title":"Analysts’ Opinions Are Mixed on These Healthcare Stocks: Geron (GERN), Zimmer Biomet Holdings (ZBH) and Recursion Pharmaceuticals (RXRX)","url":"https://stock-news.laohu8.com/highlight/detail?id=2657522957","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2657522957?lang=en_us&edition=fundamental","pubTime":"2026-08-06 03:10","pubTimestamp":1785957008,"startTime":"0","endTime":"0","summary":"Analysts have been eager to weigh in on the Healthcare sector with new ratings on Geron (GERN), Zimmer Biomet Holdings (ZBH) and Recursion Pharmace...","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/blurbs/analysts-opinions-are-mixed-on-these-healthcare-stocks-geron-gern-zimmer-biomet-holdings-zbh-and-recursion-pharmaceuticals-rxrx-blurbs-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/blurbs/analysts-opinions-are-mixed-on-these-healthcare-stocks-geron-gern-zimmer-biomet-holdings-zbh-and-recursion-pharmaceuticals-rxrx-blurbs-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["ZBH","RXRX","BK4082","BK4585","BK4504","IE0002270589.USD","LU0310799852.SGD","LU0980610538.SGD","LU1267930573.SGD","LU1201861249.SGD","LU0792757196.USD","LU0029864427.USD","BK4611","BK4588","IE00B19Z3B42.SGD","LU0211327993.USD","LU0708994859.HKD","BK4548","IE00B19Z3581.USD","LU0006061336.USD","BK4139","LU0128525929.USD","LU0477156953.USD","LU0648001328.SGD","LU0130102774.USD","IE00B7SZLL34.SGD","BK4539","BK4609","LU0211328371.USD","LU0310800379.SGD","LU0889566641.SGD","LU0130517989.USD","BK4566","GERN","LU1267930490.SGD","LU1267930813.SGD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2657390540","title":"Recursion Pharmaceuticals, Inc. Reports Results for the Quarter Ended June 30 - Earnings Summary","url":"https://stock-news.laohu8.com/highlight/detail?id=2657390540","media":"Reuters","labels":["express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2657390540?lang=en_us&edition=fundamental","pubTime":"2026-08-05 21:30","pubTimestamp":1785936652,"startTime":"0","endTime":"0","summary":"Recursion Pharmaceuticals, Inc. reports results for the quarter ended June 30 - Earnings SummaryRecursion Pharmaceuticals, Inc.RXRX.OQreported a quarterly adjusted loss of 25 cents per share for the q","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260805:nL8N44222C:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"express","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4539","BK4611","BK4609","RXRX","BK4548","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2657413541","title":"Recursion Q2 2026 earnings: Expense cuts narrow the net loss","url":"https://stock-news.laohu8.com/highlight/detail?id=2657413541","media":"TradingKey","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2657413541?lang=en_us&edition=fundamental","pubTime":"2026-08-05 18:58","pubTimestamp":1785927511,"startTime":"0","endTime":"0","summary":"Recursion’s Q2 2026 revenue fell to $7.7 million from $19.2 million as Roche and Genentech revenue declined following completion of certain project phases. GAAP diluted loss per share improved to $0.25 from $0.41, and net loss narrowed to $131.0 million from $171.9 million as R&D and G&A expenses decreased. Quarterly operating cash use rose to $105.9 million, while cash, cash equivalents and restricted cash ended June at $556.8 million. Recursion lowered its 2026 cash operating expense ceiling to below $375 million and maintained cash runway guidance into early 2028.","market":"sg","thumbnail":"https://resource.tradingkey.com/cdn/images/article/news/stock6.jpg","type":0,"news_type":0,"thumbnails":["https://resource.tradingkey.com/cdn/images/article/news/stock6.jpg"],"rights":null,"property":["earning"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tradingkey.com/news/earnings/262077414-tradingkey","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4611","RXRX","BK4548","BK4539","BK4609","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2657543089","title":"Earnings Flash (RXRX) Recursion Pharmaceuticals Posts Q2 Loss $0.25 a Share, vs. FactSet Est of $0.28 Loss","url":"https://stock-news.laohu8.com/highlight/detail?id=2657543089","media":"MT Newswires Live","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2657543089?lang=en_us&edition=fundamental","pubTime":"2026-08-05 18:45","pubTimestamp":1785926758,"startTime":"0","endTime":"0","summary":"Earnings Flash (RXRX) Recursion Pharmaceuticals Posts Q2 Loss $0.25 a Share, vs. FactSet Est of $0.28 Loss","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["BK4539","BK4611","BK4548","BK4139","BK4609","RXRX"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2657432965","title":"Recursion Pharmaceuticals Q2 Operating Revenue USD 7.303 Million Vs. IBES Estimate USD 11.9 Million","url":"https://stock-news.laohu8.com/highlight/detail?id=2657432965","media":"Reuters","labels":["express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2657432965?lang=en_us&edition=fundamental","pubTime":"2026-08-05 18:43","pubTimestamp":1785926593,"startTime":"0","endTime":"0","summary":"Aug 05 (Reuters) - Recursion Pharmaceuticals Q2 pretax profit USD -131.006 million.:((Reuters Investor Briefs; email: reutersinvestor.briefs@thomsonreuters.com))Source Date/Time = 05-AUG-202610:29:08.17 GMT","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260805:nRSD9jmn2G:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"express","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4539","BK4611","BK4609","RXRX","BK4548","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2657954328","title":"Recursion Pharmaceuticals Q2 Revenue Misses Estimates, Cuts 2026 Expense Outlook","url":"https://stock-news.laohu8.com/highlight/detail?id=2657954328","media":"Reuters","labels":["dataReport","express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2657954328?lang=en_us&edition=fundamental","pubTime":"2026-08-05 18:42","pubTimestamp":1785926539,"startTime":"0","endTime":"0","summary":"Recursion Pharmaceuticals Q2 revenue misses estimates, cuts 2026 expense outlookOverviewUS drug discovery firm's Q2 operating revenue fell and missed analyst expectationsQ2 net loss narrowed yr/yr but","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260805:nL1N4420FP:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"dataReport,express","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4611","RXRX","BK4548","BK4539","BK4609","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2657543986","title":"Recursion Pharmaceuticals Shares Fall 9% Premarket After Q2 Revenue Miss","url":"https://stock-news.laohu8.com/highlight/detail?id=2657543986","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2657543986?lang=en_us&edition=fundamental","pubTime":"2026-08-05 18:37","pubTimestamp":1785926270,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260805:nL4N44210D:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4609","BK4139","RXRX","BK4539","BK4548","BK4611"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2657543594","title":"Recursion Q2 Net Loss Narrows to $131.01 Million; Revenue Drops to $7.67 Million","url":"https://stock-news.laohu8.com/highlight/detail?id=2657543594","media":"Reuters","labels":["corporation","dataReport","express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2657543594?lang=en_us&edition=fundamental","pubTime":"2026-08-05 18:31","pubTimestamp":1785925903,"startTime":"0","endTime":"0","summary":"Recursion Q2 net loss narrows to $131.01 million; revenue drops to $7.67 millionRecursion posted Q2 net loss of USD 131 million, narrowing from USD 171.9 million a year earlier; revenue fell 59.93% to","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260805:nNDL9S66Q1:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"corporation,dataReport,express","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4611","BK4548","BK4539","RXRX","BK4139","BK4609"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2657543844","title":"Recursion Pharmaceuticals Q2 EPS $(0.25) Misses $(0.22) Estimate, Sales $7.670M Miss $11.947M Estimate","url":"https://stock-news.laohu8.com/highlight/detail?id=2657543844","media":"Benzinga Earnings","labels":["dataReport","express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2657543844?lang=en_us&edition=fundamental","pubTime":"2026-08-05 18:31","pubTimestamp":1785925860,"startTime":"0","endTime":"0","summary":"Recursion Pharmaceuticals (NASDAQ:RXRX) reported quarterly losses of $(0.25) per share which missed the analyst consensus estimate of $(0.22) by 13.64 percent. This is a 39.02 percent increase over losses of $(0.41) per","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.benzinga.com/news/earnings/26/08/60941020/recursion-pharmaceuticals-q2-eps-0-25-misses-0-22-estimate-sales-7-670m-miss-11-947m-estimate","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"dataReport,express","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4609","BK4539","BK4548","RXRX","BK4611","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2657754875","title":"Recursion Pharmaceuticals Q2 Net Income USD -131.005 Million","url":"https://stock-news.laohu8.com/highlight/detail?id=2657754875","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2657754875?lang=en_us&edition=fundamental","pubTime":"2026-08-05 18:30","pubTimestamp":1785925800,"startTime":"0","endTime":"0","summary":null,"market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260805:nPLXG5D2DP:2","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4539","BK4611","BK4609","RXRX","BK4139","BK4548"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2657548761","title":"Recursion Pharmaceuticals Inc: Reduced 2026 Cash Operating Expense Guidance to <$375 Mln","url":"https://stock-news.laohu8.com/highlight/detail?id=2657548761","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2657548761?lang=en_us&edition=fundamental","pubTime":"2026-08-05 18:30","pubTimestamp":1785925800,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260805:nPLXG5D2DP:5","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4539","BK4548","BK4609","BK4611","RXRX","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2657543891","title":"Press Release: Recursion Reports Second Quarter Financial Results; Genentech Options First Neuroscience Target into Early Discovery Program","url":"https://stock-news.laohu8.com/highlight/detail?id=2657543891","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2657543891?lang=en_us&edition=fundamental","pubTime":"2026-08-05 18:30","pubTimestamp":1785925800,"startTime":"0","endTime":"0","summary":"-- Genentech advanced the collaboration's first neuroscience target into a. joint early discovery program, providing early evidence that Recursion's. platform can generate novel, biologically validated targets for drug. -- REC-4881 : Additional Phase 2 data in Familial. Adenomatous Polyposis  to be presented at the Presidential Plenary. session at leading hereditary GI annual meeting in November 2026. -- REC-7735 : IND cleared, Phase 1/2 trial. start in 2H26; a >100× mutant-selective PI3K<ALPHA> H1047R inhibitor. designed to improve therapeutic index by enabling deep suppression of the. most common activating PI3K<ALPHA> mutation while sparing wild-type. -- Reduced 2026 cash operating expense guidance to <$375 million (from <$390","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4609","BK4548","BK4611","BK4139","BK4539","RXRX"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2656649555","title":"Recursion to Present at Bank of America SMID Cap Executive Insights Event","url":"https://stock-news.laohu8.com/highlight/detail?id=2656649555","media":"Reuters","labels":["conferences"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2656649555?lang=en_us&edition=fundamental","pubTime":"2026-08-04 20:05","pubTimestamp":1785845125,"startTime":"0","endTime":"0","summary":"Recursion to present at Bank of America SMID Cap Executive Insights eventRecursion will attend the Bank of America 2026 SMID Cap Executive Insights Event on Aug. 11, 2026.It will also participate in t","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260804:nNDLc02Phc:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"conferences","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4609","BK4539","BK4611","RXRX","BK4139","BK4548"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2656497556","title":"Recursion to Participate in Upcoming Investor Conferences","url":"https://stock-news.laohu8.com/highlight/detail?id=2656497556","media":"GlobeNewswire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2656497556?lang=en_us&edition=fundamental","pubTime":"2026-08-04 20:00","pubTimestamp":1785844800,"startTime":"0","endTime":"0","summary":"Recursion Pharmaceuticals. media@recursion.com","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2026/08/04/3338226/0/en/Recursion-to-Participate-in-Upcoming-Investor-Conferences.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4609","BK4539","BK4548","RXRX","BK4611","BK4139"],"isVideo":false,"video":null,"gpt_icon":0}],"profile":{"websiteUrl":"http://www.recursion.com;ir.recursion.com","stockEarnings":[{"period":"1week","weight":0.1076},{"period":"1month","weight":0.1745},{"period":"3month","weight":0.1628},{"period":"6month","weight":0.0234},{"period":"1year","weight":-0.2678},{"period":"ytd","weight":-0.1443}],"compareEarnings":[{"period":"1week","weight":-0.0137},{"period":"1month","weight":0.0245},{"period":"3month","weight":0.0269},{"period":"6month","weight":0.1107},{"period":"1year","weight":0.2048},{"period":"ytd","weight":0.1229}],"compareStock":{"symbol":"SPY","name":"SPDR S&P 500 ETF Trust"},"description":"Recursion Pharmaceuticals, Inc. operates as a clinical-stage biotechnology company, engages in the decoding biology by integrating technological innovations across biology, chemistry, automation, data science, and engineering to industrialize drug discovery. The company develops REC-994, which is in Phase 2 clinical trial to treat cerebral cavernous malformation; REC-2282, which is in Phase 2/3 clinical trial for the treatment of neurofibromatosis type 2; REC-4881, which is in Phase 2 clinical trial to treat familial adenomatous polyposis; REC-3964, which is in Phase 1 clinical trial to treat Clostridioides difficile infection; and REC-4881, which is in Phase 1b/2 clinical trial to treat AXIN1 or APC mutant cancers. Its preclinical stage product includes RBM39 to treat HR-proficient ovarian cancer; REC-64151 for the treatment of immune checkpoint resistance; and Anti-PD-(L)1, an orally bioavailable small molecule to improve sensitivity to immune checkpoint inhibitors in non-small cell lung cancer and additional tumors. The company has collaboration and agreement with Bayer AG; the University of Utah Research Foundation; Ohio State Innovation Foundation; Chromaderm, Inc.; Roche & Genentech; and Takeda Pharmaceutical Company Limited. Recursion Pharmaceuticals, Inc. was incorporated in 2013 and is headquartered in Salt Lake City, Utah.","yearOnYearQuotes":[{"month":1,"riseRate":0.6,"avgChangeRate":-0.035717},{"month":2,"riseRate":0.4,"avgChangeRate":0.049361},{"month":3,"riseRate":0,"avgChangeRate":-0.249219},{"month":4,"riseRate":0.4,"avgChangeRate":-0.090167},{"month":5,"riseRate":0.5,"avgChangeRate":0.076509},{"month":6,"riseRate":0.666667,"avgChangeRate":0.117519},{"month":7,"riseRate":0.666667,"avgChangeRate":0.141285},{"month":8,"riseRate":0.333333,"avgChangeRate":-0.077696},{"month":9,"riseRate":0.4,"avgChangeRate":-0.050486},{"month":10,"riseRate":0.2,"avgChangeRate":-0.079168},{"month":11,"riseRate":0.4,"avgChangeRate":0.028843},{"month":12,"riseRate":0.2,"avgChangeRate":-0.000986}],"exchange":"NASDAQ","name":"Recursion Pharmaceuticals, Inc.","nameEN":"Recursion Pharmaceuticals, Inc."},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"isLaohu8Offline":false,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.47.1","shortVersion":"4.47.1","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"Recursion Pharmaceuticals, Inc.(RXRX),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community","description":"Find the latest Recursion Pharmaceuticals, Inc.(RXRX) stock quote, history, news, and investing ideas from To The Moon - Tiger Brokers Online Investing Community to stay on top of the markets.","keywords":"Recursion Pharmaceuticals, Inc.,RXRX,Recursion Pharmaceuticals, Inc.股票,Recursion Pharmaceuticals, Inc.股票老虎,Recursion Pharmaceuticals, Inc.股票老虎国际,Recursion Pharmaceuticals, Inc.行情,Recursion Pharmaceuticals, Inc.股票行情,Recursion Pharmaceuticals, Inc.股价,Recursion Pharmaceuticals, Inc.股市,Recursion Pharmaceuticals, Inc.股票价格,Recursion Pharmaceuticals, Inc.股票交易,Recursion Pharmaceuticals, Inc.股票购买,Recursion Pharmaceuticals, Inc.股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"Recursion Pharmaceuticals, Inc.(RXRX),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community","og_description":"Find the latest Recursion Pharmaceuticals, Inc.(RXRX) stock quote, history, news, and investing ideas from To The Moon - Tiger Brokers Online Investing Community to stay on top of the markets.","og_image":"https://community-static.tradeup.com/news/9b6dafd60190235ae8e2c95f52c583a0"}}}